SEPTERNA, INC. COMMON STOCK
NASDAQ: SEPN (Septerna, Inc.)
Last update: 13 hours ago7.48
0.34 (4.76%)
| Previous Close | 7.14 |
| Open | 7.21 |
| Volume | 201,376 |
| Avg. Volume (3M) | 514,417 |
| Market Cap | 332,977,440 |
| Price / Sales | 68.82 |
| Price / Book | 0.790 |
| 52 Weeks Range | |
| Earnings Date | 27 Mar 2025 |
| Operating Margin (TTM) | -11,659.43% |
| Diluted EPS (TTM) | -7.26 |
| Quarterly Revenue Growth (YOY) | 79.70% |
| Total Debt/Equity (MRQ) | 6.07% |
| Current Ratio (MRQ) | 27.77 |
| Operating Cash Flow (TTM) | -67.47 M |
| Levered Free Cash Flow (TTM) | -25.69 M |
| Return on Assets (TTM) | -17.20% |
| Return on Equity (TTM) | -27.05% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Septerna, Inc. | Bearish | - |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 2.0 |
| Average | 1.63 |
|
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, and GLP-1R, GIPR, GCGR. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 6.81% |
| % Held by Institutions | 102.74% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 50.00 (Cantor Fitzgerald, 568.45%) | Buy |
| Median | 30.50 (307.75%) | |
| Low | 11.00 (Wells Fargo, 47.06%) | Hold |
| Average | 30.50 (307.75%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 8.74 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wells Fargo | 28 Mar 2025 | 11.00 (47.06%) | Hold | 6.10 |
| 18 Feb 2025 | 14.00 (87.17%) | Hold | 6.87 | |
| Cantor Fitzgerald | 11 Feb 2025 | 50.00 (568.45%) | Buy | 11.38 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 27 Mar 2025 | Announcement | Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results |
| 26 Feb 2025 | Announcement | Septerna to Present at TD Cowen 45th Annual Health Care Conference |
| 18 Feb 2025 | Announcement | Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |